HUP0300857A3 - Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists - Google Patents

Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Info

Publication number
HUP0300857A3
HUP0300857A3 HU0300857A HUP0300857A HUP0300857A3 HU P0300857 A3 HUP0300857 A3 HU P0300857A3 HU 0300857 A HU0300857 A HU 0300857A HU P0300857 A HUP0300857 A HU P0300857A HU P0300857 A3 HUP0300857 A3 HU P0300857A3
Authority
HU
Hungary
Prior art keywords
oxazolyl
acid derivatives
ppar agonists
arylpropionic acid
arylpropionic
Prior art date
Application number
HU0300857A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0300857A2 publication Critical patent/HUP0300857A2/hu
Publication of HUP0300857A3 publication Critical patent/HUP0300857A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0300857A 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists HUP0300857A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
HUP0300857A2 HUP0300857A2 (hu) 2003-10-28
HUP0300857A3 true HUP0300857A3 (en) 2007-03-28

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300857A HUP0300857A3 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Country Status (26)

Country Link
US (2) US6930120B2 (https=)
EP (1) EP1313716B1 (https=)
JP (1) JP2004506721A (https=)
KR (1) KR20030027054A (https=)
CN (1) CN1471517A (https=)
AT (1) ATE361283T1 (https=)
AU (1) AU2001284659A1 (https=)
BR (1) BR0113409A (https=)
CA (1) CA2418104A1 (https=)
CY (1) CY1107679T1 (https=)
CZ (1) CZ2003482A3 (https=)
DE (1) DE60128239T2 (https=)
DK (1) DK1313716T3 (https=)
EA (1) EA200300286A1 (https=)
EC (1) ECSP034504A (https=)
ES (1) ES2286137T3 (https=)
HU (1) HUP0300857A3 (https=)
IL (1) IL154110A0 (https=)
MX (1) MXPA03001558A (https=)
NO (1) NO20030729L (https=)
NZ (1) NZ523804A (https=)
PL (1) PL360744A1 (https=)
PT (1) PT1313716E (https=)
SK (1) SK1872003A3 (https=)
WO (1) WO2002016331A1 (https=)
ZA (1) ZA200300570B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509084A (ja) * 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのpparアゴニストとしての使用
AU2001284660A1 (en) 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
DE60211891T2 (de) * 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
BR0312452A (pt) 2002-07-03 2005-04-19 Hoffmann La Roche Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama)
KR100736955B1 (ko) * 2002-08-30 2007-07-09 에프. 호프만-라 로슈 아게 Ppar알파 및 ppar감마 작용제로서의 신규한 2-아릴티아졸 화합물
RU2296759C2 (ru) 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CA2503117C (en) * 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
RU2315767C2 (ru) 2002-11-25 2008-01-27 Ф.Хоффманн-Ля Рош Аг Индолилпроизводные, способ их получения, фармацевтическая композиция, способ лечения и/или профилактики заболеваний
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1658285B1 (en) * 2003-08-20 2007-05-02 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ATE350369T1 (de) 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
AU721452B2 (en) 1996-02-02 2000-07-06 Merck & Co., Inc. Antidiabetic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのpparアゴニストとしての使用
AU2001284660A1 (en) * 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
US20050245584A1 (en) 2005-11-03
EP1313716A1 (en) 2003-05-28
ES2286137T3 (es) 2007-12-01
EP1313716B1 (en) 2007-05-02
MXPA03001558A (es) 2003-06-06
NZ523804A (en) 2004-09-24
ZA200300570B (en) 2004-04-21
WO2002016331A1 (en) 2002-02-28
US6930120B2 (en) 2005-08-16
PL360744A1 (en) 2004-09-20
PT1313716E (pt) 2007-07-11
DK1313716T3 (da) 2007-08-27
JP2004506721A (ja) 2004-03-04
NO20030729D0 (no) 2003-02-14
HUP0300857A2 (hu) 2003-10-28
NO20030729L (no) 2003-04-02
IL154110A0 (en) 2003-07-31
US7345070B2 (en) 2008-03-18
CY1107679T1 (el) 2013-04-18
AU2001284659A1 (en) 2002-03-04
US20040097590A1 (en) 2004-05-20
DE60128239T2 (de) 2008-01-10
CA2418104A1 (en) 2002-02-28
ECSP034504A (es) 2003-04-25
CZ2003482A3 (cs) 2003-05-14
KR20030027054A (ko) 2003-04-03
CN1471517A (zh) 2004-01-28
EA200300286A1 (ru) 2003-08-28
SK1872003A3 (en) 2003-07-01
BR0113409A (pt) 2003-07-01
ATE361283T1 (de) 2007-05-15
DE60128239D1 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
IL147821A0 (en) Benzoic acid derivatives and their use as ppar receptor agonists
HUP0201633A3 (en) Alpha-aminosulphonyl-acetohydroxamic acid derivatives with metalloprotease inhibiting effect, preparation and use thereof
PL362917A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
IL154031A0 (en) Substituted sulfonylaminomethylbenzoic acid derivatives and preparation
HUP0300857A3 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
IL155634A0 (en) 3-arylindole derivatives and their use as cb2 receptor agonists
IL149374A0 (en) New use and novel n-azabicyclo-amide derivatives
IL149361A0 (en) Picolinic acid derivatives and their use as fungicides
AU2003206787A8 (en) Sulfonate derivatives and the use therof as latent acids
HUP0301773A3 (en) Apomorphine derivatives and methods for their use
HUP0203961A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
ZA200410054B (en) Propionic acid derivatives and their use as hPPARsactivators.
PL376363A1 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
HUP0302306A3 (en) Propionic acid derivatives with ppar-alpha activating properties
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides
IL158056A0 (en) Chemical derivatives and their use as anti-telomerase agent
AU2001291744A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
PL359668A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
SI1259515T1 (en) Thienopyridine derivatives and their use as anti-inflammatory agents
AU2001282268A1 (en) Phenantridine derivatives and their use as anti-telomerase agent
HK1057041A (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
IL156794A0 (en) Chemical derivatives and their use as anti-telomerase agent
AU8973201A (en) Biphenyl derivatives and the use thereof as integrin inhibitors
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees